Keros Therapeutics, Inc.
- KROS
- NASDAQ
- Biotechnology
- Hematology/Musculoskeletal Therapies
- Clinical-Stage Biotech
$10.66
Today −3.96%Quote Oct 16, 2026, 08:00 PM UTC
−6.16%over the last month
Max drawdown −10.8%From 1-month high −10.8%3 months +0.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$211.4M
Quote Oct 16
Next earnings
Nov 4
Expected, not confirmed
Analyst target
$20.33
+90.7% from here
Floor
$10.45
2.0% below price
Where the price sits
17 analysts
Analyst range, low to high
$18.00$23.00
- Price $10.66
- Resistance $11.09
- Consensus $20.33
The price is just above its floor. Analysts' average target sits about 91% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KROSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
92
Founded
2015